{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:03:55Z","timestamp":1757624635330,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute for Health and Care Research Applied Research Collaboration East Midlands"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is a complex relationship between pain and mood disorders, and interactions between opioids and antidepressants can affect the effectiveness and adverse effects of these medicines when taken together. However, little is known about the scale of co-prescription for these medicines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used routinely collected primary care data from the Clinical Practice Research Datalink to describe the extent of opioid and antidepressant co-prescribing in over 4.3\u00a0million adults in England. Linked data included deprivation information and hospital episode statistics admitted patient care data to improve completeness of ethnicity information. We identified all primary care prescriptions of opioids and antidepressants between 2010 and 2019 and counted if an opioid and antidepressant prescription overlapped, and if so, for how long. People were censored at the first date of a record of cancer, terminal illness, heart failure or opioid misuse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were 4,355,694 people included in the study population. Of these, 304,029 (7.0%) had an opioid and antidepressant co-prescribed at least once during the study period. The prevalence of co-prescribing increased from 35.8 per 1000 person-years in 2010 to 44.1 in 2015 and then decreased to 39.2 in 2019. Co-prescribing rates were higher in females, older age groups, people living in more deprived areas and the White ethnic group. The overall median length of the opioid and antidepressant co-prescriptions was 29 days (interquartile range: 17 to 51 days). The most commonly co-prescribed medicines were codeine and amitriptyline, co-prescribed 235,017 times to 87,274 people. The second most commonly co-prescribed combination was codeine and citalopram, co-prescribed 55,792 times to 158,812 people. Combinations of opioids and antidepressants both metabolised by CYP2D6 were also common.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There is a substantial group of people co-prescribed opioids and antidepressants in England, including combinations that may be less effective. This information will be useful to help GPs, dispensing professionals, policymakers and others understand how many people in the UK may be at risk of harm from using both types of medicines at the same time, and which groups are particularly affected. Future research should determine whether there are higher risks of adverse events in these co-prescribed groups.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12875-025-02956-1","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T05:04:50Z","timestamp":1755320690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Co-prescribing of antidepressants and opioids for non-cancer pain in England, 2010\u20132019: a descriptive study using CPRD primary care electronic health records"],"prefix":"10.1186","volume":"26","author":[{"given":"Jake","family":"Butler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca M.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Coupland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger David","family":"Knaggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Morriss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Gerrard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Waldram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth H.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"2956_CR1","volume-title":"Dependence and withdrawal associated with some prescribed medicines: an evidence review","author":"S Taylor","year":"2019","unstructured":"Taylor S, Annand F, Burkinshaw P, Greaves F, Kelleher M, Knight J, Perkins C, Tran A, White M, Marsden J. Dependence and withdrawal associated with some prescribed medicines: An evidence review. London: Public Health England; 2019."},{"issue":"3","key":"2956_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.pain.2005.08.006","volume":"117","author":"AD Wasan","year":"2005","unstructured":"Wasan AD, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain. 2005;117(3):450\u201361.\u00a0https:\/\/doi.org\/10.1016\/j.pain.2005.08.006.","journal-title":"Pain"},{"issue":"4","key":"2956_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/aln.0000000000000768","volume":"123","author":"AD Wasan","year":"2015","unstructured":"Wasan AD, Michna E, Edwards RR, Katz JN, Nedeljkovic SS, Dolman AJ, Janfaza D, Isaac Z, Jamison RN. Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology. 2015;123(4):861\u201372.\u00a0https:\/\/doi.org\/10.1097\/aln.0000000000000768.","journal-title":"Anesthesiology"},{"issue":"1","key":"2956_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.psy.0000106883.94059.c5","volume":"66","author":"MJ Bair","year":"2004","unstructured":"Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004;66(1):17\u201322.\u00a0https:\/\/doi.org\/10.1097\/01.psy.0000106883.94059.c5.","journal-title":"Psychosom Med"},{"issue":"8","key":"2956_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/JGP.0b013e3180325a2d","volume":"15","author":"SM Thielke","year":"2007","unstructured":"Thielke SM, Fan MY, Sullivan M, Unutzer J. Pain limits the effectiveness of collaborative care for depression. Am J Geriat Psychiat. 2007;15(8):699\u2013707.\u00a0https:\/\/doi.org\/10.1097\/JGP.0b013e3180325a2d.","journal-title":"Am J Geriat Psychiat"},{"key":"2956_CR6","doi-asserted-by":"publisher","unstructured":"Buckley NA, Dawson AH, Isbister GK. PRACTICE POINTER serotonin syndrome. BMJ. 2014;348:g1626.\u00a0https:\/\/doi.org\/10.1136\/bmj.g1626.","DOI":"10.1136\/bmj.g1626"},{"key":"2956_CR7","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. 2016. Available from:\u00a0https:\/\/www.fda.gov\/media\/96472\/download."},{"issue":"4","key":"2956_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cpt.3314","volume":"116","author":"NA Nahid","year":"2024","unstructured":"Nahid NA, McDonough CW, Wei YJJ, Cicali EJ, Gong Y, Fillingim RB, Johnson JA. Use of CYP2D6 inhibitors with CYP2D6 opioids: association with emergency department visits for pain. Clin Pharmacol Ther. 2024;116(4):1005\u201312.\u00a0https:\/\/doi.org\/10.1002\/cpt.3314.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2956_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/ph17020205","volume":"17","author":"S Park","year":"2024","unstructured":"Park S, Lee GH, Kim S, Kim S, Kim Y, Choi SA. Risk Factors for Respiratory Depression Associated with Tramadol Based on the Global Pharmacovigilance Database (VigiBase). Pharmaceuticals. 2024;17(2).\u00a0https:\/\/doi.org\/10.3390\/ph17020205.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"2956_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s11606-019-05545-y","volume":"35","author":"JN Cho","year":"2020","unstructured":"Cho JN, Spence MM, Niu F, Hui RTL, Gray P, Steinberg S. Risk of overdose with exposure to prescription opioids, benzodiazepines, and non-benzodiazepine sedative-hypnotics in adults: a retrospective cohort study. J Gen Intern Med. 2020;35(3):696\u2013703.\u00a0https:\/\/doi.org\/10.1007\/s11606-019-05545-y.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2956_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/schbul\/sbab116","volume":"48","author":"AG Szmulewicz","year":"2022","unstructured":"Szmulewicz AG, Bateman BT, Levin R, Huybrechts KF. Risk of overdose associated with co-prescription of antipsychotics and opioids: A population-based cohort study. Schizophr Bull. 2022;48(2):405\u201313.\u00a0https:\/\/doi.org\/10.1093\/schbul\/sbab116.","journal-title":"Schizophr Bull"},{"key":"2956_CR12","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1136\/bmj.l1508","volume":"364","author":"G Iacobucci","year":"2019","unstructured":"Iacobucci G. NHS prescribed record number of antidepressants last year. BMJ. 2019;364:1508.\u00a0https:\/\/doi.org\/10.1136\/bmj.l1508.","journal-title":"BMJ"},{"key":"2956_CR13","unstructured":"NICE. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. 2021. Available from:\u00a0https:\/\/www.nice.org.uk\/guidance\/ng193."},{"key":"2956_CR14","volume-title":"Dependence and withdrawal associated with some prescribed medicines: An evidence review, Corrected edition","author":"S Taylor","year":"2020","unstructured":"Taylor S, Annand F, Burkinshaw P, Greaves F, Kelleher M, Knight J, Perkins C, Tr\u00e0n\u0302 A, White M, Marsden J, et al. Dependence and withdrawal associated with some prescribed medicines: An evidence review, Corrected edition. London: Public Health England; 2020."},{"key":"2956_CR15","doi-asserted-by":"publisher","unstructured":"Jani M, Yimer BB, Sheppard T, Lunt M, Dixon WG. Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. PLoS Med. 2020;17(10):e1003270. https:\/\/doi.org\/10.1371\/journal.pmed.1003270.","DOI":"10.1371\/journal.pmed.1003270"},{"key":"2956_CR16","unstructured":"NHS England. Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: Framework for action for integrated care boards (ICBs) and primary care. 2023. Available from:\u00a0https:\/\/www.england.nhs.uk\/long-read\/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms\/."},{"issue":"3","key":"2956_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.\u00a0https:\/\/doi.org\/10.1093\/ije\/dyv098.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"2956_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/ije\/dyx015","volume":"46","author":"A Herbert","year":"2017","unstructured":"Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol. 2017;46(4):1093\u2013i1093.\u00a0https:\/\/doi.org\/10.1093\/ije\/dyx015.","journal-title":"Int J Epidemiol"},{"key":"2956_CR19","unstructured":"Joint Formulary Committee. British National Formulary [online]. Available from:\u00a0https:\/\/www.medicinescomplete.com\/."},{"issue":"1","key":"2956_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12877-023-04143-2","volume":"23","author":"RM Joseph","year":"2023","unstructured":"Joseph RM, Knaggs RD, Coupland CAC, Taylor A, Vinogradova Y, Butler D, Gerrard L, Waldram D, Iyen B, Akyea RK, et al. Frequency and impact of medication reviews for people aged 65 years or above in UK primary care: an observational study using electronic health records. BMC Geriatr. 2023;23(1):435.\u00a0https:\/\/doi.org\/10.1186\/s12877-023-04143-2.","journal-title":"BMC Geriatr"},{"issue":"7","key":"2956_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/pds.4440","volume":"27","author":"SR Pye","year":"2018","unstructured":"Pye SR, Sheppard T, Joseph RM, Lunt M, Girard N, Haas JS, Bates DW, Buckeridge DL, van Staa TP, Tamblyn R, et al. Assumptions made when preparing drug exposure data for analysis have an impact on results: an unreported step in pharmacoepidemiology studies. Pharmacoepidem Dr S. 2018;27(7):781\u20138.\u00a0https:\/\/doi.org\/10.1002\/pds.4440.","journal-title":"Pharmacoepidem Dr S"},{"key":"2956_CR22","unstructured":"Baxter K, Preston CL, editors. Stockley\u2019s Drug Interactions. [online]. Available from:\u00a0http:\/\/www.medicinescomplete.com\/."},{"issue":"2","key":"2956_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/S0047279400020341","volume":"16","author":"P Townsend","year":"1987","unstructured":"Townsend P. Deprivation. J Social Policy. 1987;16(2):125\u201346.\u00a0http:\/\/dx.doi.org\/10.1017\/S0047279400020341.","journal-title":"J Social Policy"},{"key":"2956_CR24","doi-asserted-by":"publisher","unstructured":"Krassowski M, ComplexUpset. 2020. Available from:\u00a0https:\/\/doi.org\/10.5281\/zenodo.3700590.","DOI":"10.5281\/zenodo.3700590"},{"issue":"12","key":"2956_CR25","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","volume":"20","author":"A Lex","year":"2014","unstructured":"Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: visualization of intersecting sets. IEEE Trans Vis Comput Graph. 2014;20(12):1983\u201392.\u00a0https:\/\/doi.org\/10.1109\/TVCG.2014.2346248.","journal-title":"IEEE Trans Vis Comput Graph"},{"key":"2956_CR26","doi-asserted-by":"publisher","first-page":"100205","DOI":"10.1016\/j.jadr.2021.100205","volume":"6","author":"HM Lalji","year":"2021","unstructured":"Lalji HM, McGrogan A, Bailey SJ. An analysis of antidepressant prescribing trends in England 2015\u20132019. J Affect Disord Rep. 2021;6:100205.\u00a0https:\/\/doi.org\/10.1016\/j.jadr.2021.100205.","journal-title":"J Affect Disord Rep"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-02956-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:48:16Z","timestamp":1757429296000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-025-02956-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2956"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-02956-1","relation":{},"ISSN":["2731-4553"],"issn-type":[{"type":"electronic","value":"2731-4553"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study used anonymised data provided by the Clinical Practice Research Datalink (CPRD). CPRD has ethics approval from the NHS Health Research Authority to support research using anonymised patient data (East Midlands\u2013 Derby Research Ethics Committee, UK, reference 21\/EM\/0265). Access to CPRD data is subject to protocol approval through CPRD\u2019s Research Data Governance (RDG) Process, Medicines & Healthcare products Regulatory Agency, UK. The study protocol was approved by CPRD\u2019s RDG in October 2022, and can be made available upon request (protocol number 22_002047). Patient consent is not required for GP practices to share data with CPRD, as no identifiable patient information is shared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->E<!--Emphasis Type='Bold' removed-->thics<!--Emphasis Type='Bold' removed--> approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AA is National Clinical Director for Prescribing for NHS England. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}